|
Post by xanet on Oct 24, 2018 6:45:23 GMT -5
|
|
|
Post by kite on Oct 24, 2018 6:53:31 GMT -5
Can MB administrators create a separate topic for just "All About UTHR"?
|
|
|
Post by uvula on Oct 24, 2018 8:29:00 GMT -5
Can MB administrators create a separate topic for just "All About UTHR"? IMHO uthr stuff might as well be part of "all about mnkd", particularly since there is NO mnkd news lately that is independent from uthr.
|
|
|
Post by mnholdem on Oct 24, 2018 9:04:46 GMT -5
Can MB administrators create a separate topic for just "All About UTHR"? CEO Castagna did suggest that UTC may have some relevant news in October that is related to MannKind. Perhaps it will be the announcement of the specific API they've paid $10M to have MannKind research?
Otherwise, I'd agree with you that United Therapeutics activities that are not related to the MannKind-UTC Agreement would be best posted under other biotech stocks.
|
|
|
Post by slugworth008 on Oct 24, 2018 9:08:28 GMT -5
I hate to be the antagonist, but what if they do not mention it at all? Do we consider this another catch/kill partnership if that is the case? I don't believe UTHR will sanofi us - JMHO
|
|
|
Post by matt on Oct 24, 2018 9:57:07 GMT -5
1. When they expect to complete Phase 3 trials 2. When they expect to begin marketing the drug 3. Projected revenue and market penatration 4. MNKD's royalty % Some guesses on your questions: 1. UTHR has to start the trial first, and that requires completion of the formulation work. Give it a year from today, at least. 2. Standard FDA approval cycle is nine months from submission of the NDA, and it typically takes a minimum of 2-3 months from the end of Phase III to compile the NDA filing. Since this is an older drug, FDA will likely focus on the dosing and adverse events profile more than the safety of the drug itself. Adding 1 and 2 together gives you an expected date about 24 months out, maybe a few months shorter if the Phase III is exceedingly clean with few problems. Six months after the filing of the NDA is the best that can be expected for a drug that is available in other formulations. FDA has moved faster than six months, but only for novel drugs where patients have no acceptable alternative therapeutics, and even "accelerated approval" only shortens the time line by two months (i.e. from a benchmark of nine months to seven). 3. That is TBD. The price point UTHR selects will determine how well insurance will cover the new formulation, the competition's (Liquida) success or failure will have a lot to do with whether this is a highly competitive market or whether UTHR has exclusivity for a while. Since UTHR owns the market at present and any sales of a TS formulation will cannibalize their existing business, there will be a trade-off that is highly influenced by manufacturing cost and operating profit margins. Don't expect UTHR to be very transparent about those numbers. 4. Companies very, very, very rarely disclose that information. Almost all partnerships have the royalty and milestones sections redacted and those sections are given the protection of a Confidential Treatment Order by the SEC, typically for an initial five years but renewable. Companies paying royalties never want to let the market know how much they are willing to pay as that is important information their competitors would like to know, while companies receiving the royalties and milestones would love to talk about it. Normally the company writing the checks can demand confidential treatment.
|
|
|
Post by boca1girl on Oct 24, 2018 10:50:04 GMT -5
In regards to number 1 and 2: MNKD management indicated that the drug was Phase III ready and that the approval process would be relatively quick. I can’t argue months or an exact timeline, but your estimate seems overly pessimistic compared with what MNKD management had said previously. But we need that timeline come from United now.
In regards to number 4: MNKD already disclosed the royalty % as low double digits. MNKD had previously disclosed the % split on the Sanofi deal as 65/35 on net profits.
|
|
|
Post by mango on Oct 24, 2018 17:45:23 GMT -5
October 24, 2018United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its third quarter 2018 financial results before the market opens on Wednesday, October 31, 2018. United Therapeutics will host a teleconference on Wednesday, October 31, 2018, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 4179147. This teleconference is also being webcast and can be accessed via United Therapeutics' website at ir.unither.com/events.cfm. About United TherapeuticsUnited Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment and society – will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. [uthr‑g] Forward-looking StatementsStatements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the future of our business, our expectation of long-term success, and our efforts to develop organ transplantation technologies. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission that could cause actual results to differ materially from anticipated results. Such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 24, 2018 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. ir.unither.com/news-releases/news-release-details/united-therapeutics-corporation-report-third-quarter-2018
|
|
|
Post by letitride on Oct 24, 2018 17:59:58 GMT -5
October 24, 2018United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its third quarter 2018 financial results before the market opens on Wednesday, October 31, 2018. United Therapeutics will host a teleconference on Wednesday, October 31, 2018, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 4179147. This teleconference is also being webcast and can be accessed via United Therapeutics' website at ir.unither.com/events.cfm. About United TherapeuticsUnited Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment and society – will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. [uthr‑g] Forward-looking StatementsStatements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the future of our business, our expectation of long-term success, and our efforts to develop organ transplantation technologies. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission that could cause actual results to differ materially from anticipated results. Such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 24, 2018 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. ir.unither.com/news-releases/news-release-details/united-therapeutics-corporation-report-third-quarter-2018 Happy Halloween!
|
|
|
Post by mango on Oct 24, 2018 19:30:29 GMT -5
October 24, 2018United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its third quarter 2018 financial results before the market opens on Wednesday, October 31, 2018. United Therapeutics will host a teleconference on Wednesday, October 31, 2018, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 4179147. This teleconference is also being webcast and can be accessed via United Therapeutics' website at ir.unither.com/events.cfm. About United TherapeuticsUnited Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment and society – will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. [uthr‑g] Forward-looking StatementsStatements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the future of our business, our expectation of long-term success, and our efforts to develop organ transplantation technologies. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission that could cause actual results to differ materially from anticipated results. Such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 24, 2018 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. ir.unither.com/news-releases/news-release-details/united-therapeutics-corporation-report-third-quarter-2018 Happy Halloween! "United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment and society – will sustain our success in the long term." I really like that statement. Such a great partner for both MannKind.
|
|
|
Post by itellthefuture777 on Oct 24, 2018 21:44:47 GMT -5
Anybody check the clinical trials website lately? Hmmm
|
|
|
Post by mango on Oct 24, 2018 23:07:13 GMT -5
Anybody check the clinical trials website lately? Hmmm The suspense is killing me.....
|
|
|
Post by itellthefuture777 on Oct 25, 2018 15:30:25 GMT -5
Anybody check the clinical trials website lately? Hmmm The suspense is killing me..... My guess is the scrips take a leap up...6 weeks ago commercials..should show an impact..not much because of hurricanes and such..but previously not advertised..takes about a month to get appointment..so..about this Friday I suspect a move up..followed by UTH..followed by these clinical results..followed by more partners..followed by more clinical results and sales..
|
|
|
Post by mango on Oct 25, 2018 17:12:49 GMT -5
The suspense is killing me..... My guess is the scrips take a leap up...6 weeks ago commercials..should show an impact..not much because of hurricanes and such..but previously not advertised..takes about a month to get appointment..so..about this Friday I suspect a move up..followed by UTH..followed by these clinical results..followed by more partners..followed by more clinical results and sales.. I like it when you're here to tell the future. 🕺🏻
|
|
|
Post by uvula on Oct 31, 2018 7:47:48 GMT -5
|
|